MDAI
Spectral AI, Inc.Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsBULLISH
Q2 2026: 6 added (0 new), 1 trimmed or exited.
- EstimatesRISING
Current-quarter EPS estimate −$0.145 → −$0.135 over 90 days.
- Short sellersSTEADY
Short interest +6.8% to 2.35M shares. 18.1 days to cover, ≈7.3% of shares.
- TrendDOWNTREND
6% below its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | ADD | $1.7M |
| UBS Group AG | ADD | $390.7K |
| GEODE CAPITAL MANAGEMENT, LLC | TRIM | $385.2K |
| BlackRock, Inc. | ADD | $279.9K |
| NORTHERN TRUST CORP | ADD | $87.4K |
| MORGAN STANLEY | ADD | $23.9K |
| WOLVERINE ASSET MANAGEMENT LLC | ADD | $14.1K |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | $442.8K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
last action May 2026Price is below the lowest target. Median implies +239%.Targets as of Oct 26, 2026.
| Date | Firm | Rating |
|---|---|---|
| May 27, 2026 | BTIG MAINTAIN | Buy |
| May 26, 2026 | BTIG MAINTAIN | Buy |
Insider ledger
Form 4| Date | Insider | Type | Value |
|---|---|---|---|
| Sep 28, 2026 | DiMaio John Michael Director | AWARD | $51.8K |
| Sep 23, 2026 | DiMaio John Michael Director | AWARD | $100.2K |
| Sep 21, 2026 | DiMaio John Michael Director | AWARD | $35.5K |
| Sep 18, 2026 | DiMaio John Michael Director | AWARD | $17.7K |
| Sep 11, 2026 | DiMaio John Michael Director | AWARD | $35.0K |
| Sep 10, 2026 | DiMaio John Michael Director | AWARD | $15.6K |
| Aug 13, 2026 | DiMaio John Michael Director | AWARD | $57.4K |
| Jun 29, 2026 | DiMaio John Michael Director | AWARD | $25.9K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.14 | -$0.15–-$0.12 | +10.0% | $5.3M |
| Next Q | -$0.13 | -$0.14–-$0.12 | +7.1% | $5.7M |
| Current FY | -$0.47 | -$0.53–-$0.39 | +7.6% | $18.5M |
| Next FY | -$0.31 | -$0.44–-$0.21 | +13.9% | $32.4M |
Short side
FINRA· Sep 30, 2026SecBot reports
2 filings · 3 press releases · 0 bullish · 0 bearish · 2 neutral- NEUTRAL 8-KAug 12, 2026
Spectral AI reported Q2 2026 results with R&D revenue declining to $3.5M (from $5.1M YoY) as BARDA…
The revenue miss and deteriorating adjusted EBITDA signal that the BARDA contract transition is pressuring near-term financials more than expected, but the FDA clearance and reiterated guidance…
- NEUTRAL 8-KJul 8, 2026
Spectral AI appointed Darcy Bajko as Chief Commercial Officer, effective July 31, 2026, to lead…
This is a routine C-suite hire signaling the company's shift to commercialization post-FDA clearance. Monitor for first sales announcements and the next quarterly report for revenue trajectory. No…
- MIXED PRESS RELEASEMar 24, 2026
Spectral AI reported FY 2025 revenue of $19.7 million, down 33.5% YoY, with Q4 revenue halving to…
Monitor FDA decision on De Novo 510(k) submission for DeepView System — commercialization remains key to future revenue. Despite improved cash and reduced losses, declining R&D revenue and lack of…
- BULLISH PRESS RELEASEMar 18, 2026
Spectral AI (MDAI) announced $31.7 million in additional non-dilutive funding from BARDA to…
This funding de-risks the path to FDA authorization and commercialization of the DeepView System. Traders should monitor for upcoming FDA decision timelines and potential near-term catalysts. The…
All MDAI filing & press-release reports (5)
- 8-K reportAug 12, 2026
- 8-K reportJul 8, 2026
- PRESS-RELEASE reportMar 24, 2026
- PRESS-RELEASE reportMar 18, 2026
- PRESS-RELEASE reportMar 10, 2026